Benefit From Fractionated Dose-Dense Chemotherapy in Patients With Poor Prognostic Ovarian Cancer: ICON-8 Trial.
Olivier ColombanAndrew ClampAdrian CookIain A McNeishBenoit YouPublished in: JCO clinical cancer informatics (2023)
Fractionated dose-dense chemotherapy might be beneficial for patients belonging to the poor prognostic group characterized by lower tumor chemosensitivity assessed with the online calculator CA-125-Biomarker Kinetics and incomplete debulking surgery. Further investigation in the future SALVOVAR trial is warranted.
Keyphrases
- end stage renal disease
- phase iii
- clinical trial
- study protocol
- locally advanced
- phase ii
- ejection fraction
- minimally invasive
- newly diagnosed
- social media
- randomized controlled trial
- neoadjuvant chemotherapy
- peritoneal dialysis
- healthcare
- small cell lung cancer
- radiation therapy
- patient reported outcomes
- acute coronary syndrome
- coronary artery bypass
- open label
- double blind
- squamous cell carcinoma
- rectal cancer
- surgical site infection